Why Armata Pharmaceuticals, Inc.’s (ARMP) Stock Is Down 6.26%
As of Friday, August 28, Armata Pharmaceuticals, Inc.’s ARMP share price has dipped by 6.26%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
Commentary & Analysis
Why Armata Pharmaceuticals, Inc.’s (ARMP) Stock Is Down 6.06%
As of Thursday, August 27, Armata Pharmaceuticals, Inc.’s ARMP share price has dipped by 6.06%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Armata Pharmaceuticals, Inc.’s (ARMP) Stock Is Up 5.61%
As of Tuesday, August 25, Armata Pharmaceuticals, Inc.’s ARMP share price has surged by 5.61%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Armata Pharmaceuticals, Inc.’s (ARMP) Stock Is Up 14.71%
As of Friday, August 21, Armata Pharmaceuticals, Inc.’s ARMP share price has surged by 14.71%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Armata Pharmaceuticals, Inc.’s (ARMP) Stock Is Up 9.65%
As of Wednesday, August 19, Armata Pharmaceuticals, Inc.’s ARMP share price has surged by 9.65%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | ARMP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $196.3 | $282.5 | 27% |
|
| Shares Out (Mil) | 62.0 | 54.1 | 53% |
|
| Institutional Ownership | 96.1% | 92.9% | 69% |
|
| Float (Mil) | 11.9 | 41.5 | 21% |
|
| Beta | 1.33 | 0.94 | 77% |
|
| Avg Daily Volume (000s) | 108 | 469 | 37% |
|
| Price Change (52-week) |
111.2% | 59.1% | 93% |
|
| Growth | ARMP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 43.7% | 14.1% | 94% |
|
| Net Income (5yr) | (50.9%) | (10.1%) | 7% |
|
| EPS (5yr) | (28.9%) | 15.9% | 9 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.8%) | (15.6%) | 47% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($0.380) | ($1.865) | ($1.445) | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | 0 | 1 | |
| # Rev Down | na | 0 | 0 | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | 39.7% | (61.1%) | (77.3%) | |
| Financials | ARMP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $6 | $37 | 6% |
|
| Net Income (TTM) (Mil) | ($192) | ($43) | 7% |
|
| EPS (TTM) | ($5.270) | ($1.500) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($25) | ($31) | 13% |
|
| Net Cash Flow (TTM) (Mil) | $18 | $2 | 61% |
|
| Long-Term Debt (Q1) (Mil) | $68 | $4 | 41% |
|
| Enterprise Value (Q1) (Mil) | $460 | $195 | 33% |
|
| Valuation | ARMP | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.78 | na |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ARMP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (217.4%) | 66.9% | 1% |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (225.1%) | (47.6%) | 2% |
|
| ROE | 127.8% | (55.0%) | 97% |
|
| Liabilities to Assets | 357.0% | 29.6% | 100% |
|
| F-Score | 2 | 3 | 7% |
|
Armata Pharmaceuticals, Inc. did not pass any screens on 9/1/2026.
